Key Specifications Table
Pricing & Availability
An invalid quantity was specified. The product quantity has been adjusted.
|5.04041.0001||Glass bottle||100 mg||
|Overview||A cell-permeable uricosuric agent that, in addition to its known efficacy in gout treatment, acts as a reversible CaCC blocker and is reported to be more potent than NFA (Cat. No. 481987) and NPPB (Cat. No. 484100) in suppressing 500 nM Ionomycin- (Cat. Nos. 407950, 407952, and 407953) induced I- influx in TMEM16A-expressing HEK293 cells (IC50 = 9.97, 140, and 150 µM, respectively) as well as in blocking voltage-gated Cl- current in TMEM16B-expressing HEK293 cells, while exhibiting much reduced potency against ENaC (α, β, and γ) or CFTR. Shown to significantly reduce mucin secretion from NHBE (normal human bronchial epithelial) and suppress human ASM (airway smooth muscle) contraction upon muscarinic receptor stimulation.|
|Synonyms||(3,5-dibromo-4-hydroxyphenyl)(2-ethylbenzofuran-3-yl)methanone, ANO Blocker IV, Anoctamin Blocker IV, BBR, CaCC Blocker IV, Calcium-Activated Chloride Channel Blocker IV, TMEM16 Blocker IV|
|Structure formula Image|
|Purity||≥97% by HPLC|
|Safety Information according to GHS|
|R Phrase||R: 25
Toxic if swallowed.
|S Phrase||S: 45
In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible).
|Product Usage Statements|
|Packaged under inert gas||Packaged under inert gas|
|Kobayashi, K., et al. 2012. Drug Metab. Pharmacokinet. In press.
Zhang, C.H., et al. 2013. Am. J. Respir. Crit. Care Med. 187, 374.
Huang, F., et al. 2012. Proc. Natl. Acad. Sci. USA. 109, 16354.
Fujimori, S., et al. 2011. Nucleosides Nucleotides Nucleic Acids 30, 1035.
Perez-Ruiz, F., et al. 1998. Ann. Rheum. Dis. 57, 545.
Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.